Robert Davis, Merck CEO
November 4, 2021 07:28 AM EDTUpdated 10:00 AM
Coronavirus

Covid-19 roundup: Mod­er­na's stock plunges af­ter low­er sales fore­cast is re­vealed; Re­gen­eron sees $804M in Q3 mon­o­clon­al an­ti­body sales

Nicole DeFeudis

Editor

Mod­er­na’s stock $MR­NA plunged more than 14% in pre­mar­ket trad­ing on Thurs­day af­ter the biotech cut its end-of-year vac­cine sales fore­cast.

Ac­cord­ing to its Q3 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

Iterum wins ap­proval for new oral an­tibi­ot­ic for UTIs. Now it wants a part­ner

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times